Edward Schuka, MD
Family Medicine · Pensacola, FLNPI 1194712554
Payments from drug & device makers
Across 407 payments — averaging $17.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Lilly USA, LLC$791
- AbbVie$777
- Novo Nordisk$498
- Boehringer Ingelheim$438
- Astellas Pharma US Inc$430
- plus $3K from 29 others
What the payments were for
- Food & beverage$7,088100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 33 | $1,118 |
| Lilly USA, LLC | 60 | $791 |
| AbbVie(2 entities) | 66 | $777 |
| Novo Nordisk | 31 | $498 |
| Boehringer Ingelheim | 24 | $438 |
| Astellas Pharma US Inc | 24 | $430 |
| Pfizer | 23 | $389 |
| Amgen | 17 | $341 |
| GSK | 18 | $277 |
| Johnson & Johnson | 14 | $259 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $257 |
| Exact Sciences | 12 | $219 |
| Sumitomo Pharma America, Inc. | 12 | $197 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $170 |
| Edwards Lifesciences | 1 | $134 |
| Merck | 6 | $100 |
| Sanofi-aventis U.S. LLC | 5 | $81 |
| Phathom Pharmaceuticals, Inc. | 8 | $79 |
| Axsome Therapeutics, Inc. | 3 | $67 |
| Kowa Pharmaceuticals America, Inc. | 5 | $62 |
| Harmony Biosciences LLC | 2 | $59 |
| Bayer | 3 | $56 |
| Amarin Pharma, Inc. | 2 | $40 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Tonix Medicines, Inc. | 1 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $26 |
| Abbott | 1 | $24 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Novartis | 1 | $16 |
| Shire North American Group Inc | 1 | $13 |
| Eisai Inc. | 1 | $12 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,088 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 127 | $135,505 |
| MounjaroTirzepatide | 114 | $118,904 |
| EliquisApixaban | 120 | $113,938 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 92 | $83,334 |
| EnbrelEtanercept | 11 | $82,789 |
| TrulicityDulaglutide | 53 | $76,140 |
| XareltoRivaroxaban | 70 | $62,404 |
| OzempicSemaglutide | 49 | $57,961 |
| JanuviaSitagliptin Phosphate | 51 | $49,543 |
| FarxigaDapagliflozin Propanediol | 49 | $44,281 |
| LinzessLinaclotide | 34 | $36,924 |
| MyrbetriqMirabegron | 37 | $26,043 |
| GemtesaVibegron | 19 | $22,814 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $19,706 |
| TradjentaLinagliptin | 14 | $14,740 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $791 | $195,043167 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $438 | $162,352159 claims |
| PfizerEliquis | $389 | $113,938120 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $277 | $93,599113 claims |
| AmgenEnbrel | $341 | $82,78911 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,118 | $73,53890 claims |
| Johnson & JohnsonXarelto | $259 | $62,40470 claims |
| Novo NordiskOzempic | $498 | $57,96149 claims |
| MerckJanuvia | $100 | $49,54351 claims |
| AbbVieLinzess | $777 | $36,92434 claims |
| Astellas Pharma US IncMyrbetriq | $430 | $26,04337 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $197 | $22,81419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Pensacola
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.